Has Deepika Darbari received payments from drug or device companies?

Yes. Drug and device makers reported $96,560 in general payments to Deepika Darbari across 102 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Deepika Darbari did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Deepika Darbari come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Deepika Darbari

Pediatric Hematology-Oncology · Washington, DCNPI 1992890131

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $72,269 of the $96,560 with a category attached, or 74.8%. 9 manufacturers reported payments, led by Novo Nordisk at 32.8% of the total. Among pediatric hematology-oncology clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$96,560in general payments, 2019–2025

Across 102 payments — averaging $946.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$32K
Novartis$18K
Pfizer$14K
Global Blood Therapeutics, Inc.$12K
Octapharma USA, Inc.$9K
Merck$6K
plus $5K from 3 others

$65,058in research payments, 2019–2025

Across 16 payments — averaging $4066.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$35K
Global Blood Therapeutics, Inc.$20K
Pfizer$10K
Novo Nordisk$125

What the payments were for

Consulting fees$72,26975%
Speaking & faculty fees$5,2205%
Travel & lodging$14,98516%
Food & beverage$4,0864%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	25	$31,710
Novartis	26	$18,339
Pfizer	16	$14,074
Global Blood Therapeutics, Inc.	3	$11,818
Octapharma USA, Inc.	5	$9,147
Merck	7	$6,279
Agios Pharmaceuticals, Inc.	17	$5,125
Vertex	2	$45
Genetix Biotherapeutics Inc	1	$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

OXBRYTA$19,012
ADAKVEO$17,672
PYRUKYND$4,835
VYNDAMAX$3,710
KEYTRUDA$479
COSENTYX$388

How this compares

$96,560 in reported general payments places this provider in the 95th percentile of 46 pediatric hematology-oncology providers in District of Columbia.

See all pediatric hematology-oncology providers in District of Columbia →

Other pediatric hematology-oncology in Washington

Caterina MinnitiWashington$478K
Michael GuerreraWashington$314K
Naomi LubanWashington$27K
Holly MeanyWashington$23K
Anne AngiolilloWashington$22K
Eugene HwangWashington$21K
Gary KupferWashington$21K
Catherine BollardWashington$15K
James TaylorWashington$14K
Suvankar MajumdarWashington$11K

See the full list for District of Columbia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →